Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.